peptides women FAQ

Start with the lowest effective dose (10mg MK-677 daily or 100mcg GHRP-2 once daily before bed) and monitor fasting glucose weekly for the first month. Growth hormone and IGF-1 can transiently reduce insulin sensitivity, but this effect is dose-dependent and reversible. Women with baseline insulin resistance (fasting glucose above 100mg/dL or HbA1c above 5.7%) should prioritize metabolic optimization first. Consider pairing with berberine or metformin under physician guidance. If fasting glucose rises above 110mg/dL during the first 4 weeks, reduce the dose by 50% or discontinue until metabolic markers stabilize.

BPC-157 and thymosin beta-4 administered near affected joints accelerate repair at a structural level. Not just symptom masking. BPC-157 increases blood vessel formation in poorly vascularized tissues like tendons and cartilage; thymosin beta-4 rebuilds the collagen scaffolding. Women report 40–60% pain reduction and improved range of motion within 4–6 weeks of localized BPC-157 injection protocols. Chronic joint pain in perimenopause often reflects cumulative microtrauma compounded by estrogen-dependent collagen degradation. Addressing the underlying repair deficit produces lasting improvement, not temporary relief.